Yiduo Hu, M.D., Ph.D.

Dr Hu is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Kansas Medical Center and a member of the KU Cancer Center.

He received his MD degree from the Columbia University College of Physicians and Surgeons in New York and completed his clinical training in Internal Medicine and Hematology/Medical Oncology at the Yale University/Yale New Haven Hospital. He also earned a PhD degree in Genetics from Case Western Reserve University in Cleveland Ohio, followed by a postdoctoral research fellowship at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts.

At KUMC, he is specialized in breast cancer medical oncology and partners with providers from multidisciplinary teams to provide care to patients who are diagnosed with breast cancer. His clinical interests include triple negative breast cancer, HER2 positive breast cancer, early onset breast cancer, and breast cancer associated with genetic cancer predisposition syndromes.

Dr Hu has a long-standing research interest in basic and translational breast cancer research, and his focused areas of research include DNA damage and genome stability control, cancer predisposition syndromes associated with defective DNA repair, and the crosstalk between DNA damage, chromosomal instability, and tumor immune responses. He has published many articles in high impact research journals and his work is recognized by awards from organizations including American Association for Cancer Research, European Association for Cancer Research, American Society of Clinical Oncology, and US Department of Defense. His overarching research goal is to develop novel biomarkers and identify new therapeutic targets to promote personalized breast cancer treatment.

His current research topics include:
1. BRCA1 poly-ADP-ribosylation and its roles in preventing chromosome instability and innate immune responses.
2. Novel biomarkers for immunotherapy and targeted therapy such as PARP inhibitors utilizing liquid biopsy, digital pathology, and high sensitivity mass spectrometry technologies.
3. Strategies to implement personalized treatment for patients with early-stage triple negative, HER2 positive, or high-risk HR positive breast cancer.

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Alpha-fetoprotein-thymidine kinase-luciferase knockin mice: a novel model for dual modality longitudinal imaging of tumorigenesis in liver.

Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.

Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib.

Effect of Recql5 deficiency on the intestinal tumor susceptibility of Apc(min) mice.

Histone H2A.Z controls a critical chromatin remodeling step required for DNA double-strand break repair.

PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair.

Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain genomic integrity after replication stress.

Relations between mutant KRAS and TP53 subtypes and other co-mutations in pancreatic cancer

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.